metformin alkaloid - int 500 mg film - coated tablets
500 mg film - coated tablets
metformin alkaloid - int 850 mg film - coated tablets
850 mg film - coated tablets
metformin alkaloid - int 1000 mg film - coated tablets
1000 mg film - coated tablets
sunitinib alkaloid - int 12,5 mg hard capsules
12,5 mg hard capsules
sunitinib alkaloid - int 25 mg hard capsules
25 mg hard capsules
sunitinib alkaloid - int 50 mg hard capsules
50 mg hard capsules
nifuroxazide alkaloid - int 200 mg/5 ml oral suspension
200 mg/5 ml oral suspension
nifuroxazide alkaloid - int 100 mg capsules, hard
100 mg capsules, hard
nifuroxazide alkaloid - int 200 mg capsules, hard
200 mg capsules, hard
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - доксорубицин хидрохлорид - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Антинеопластични средства - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).